Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY22 results · Jan–Mar 2022
Solara Active Pharma Sciences reported revenue from operations of ₹360.82 crore (down 18.8% from Q4 FY21) and net profit of ₹1.81 crore (down 96.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 360.82 | 444.21 | −18.8% | 100.34 | +259.6% |
| Other income | 6.07 | 9.78 | −37.9% | 4.73 | +28.3% |
| Total income | 366.89 | 453.99 | −19.2% | 105.07 | +249.2% |
| Profit before tax | (31.00) | 56.62 | Turned loss | (139.89) | Loss narrowed |
| Net profit for the period | 1.81 | 56.61 | −96.8% | (139.89) | Turned profit |
| Attributable to shareholders of the company | 1.88 | 56.65 | −96.7% | (139.87) | Turned profit |
| EPS, basic (₹) | 0.53 | 15.57 | −96.6% | (38.93) | Turned profit |
| Net margin (%) | 0.5 | 12.7 | -139.4 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 360.82 | 444.21 | −18.8% | 100.34 | +259.6% |
| Other income | 4.69 | 9.86 | −52.4% | 4.76 | −1.5% |
| Total income | 365.51 | 454.07 | −19.5% | 105.10 | +247.8% |
| Profit before tax | (32.88) | 57.15 | Turned loss | (139.57) | Loss narrowed |
| Net profit for the period | 0.22 | 57.15 | −99.6% | (139.57) | Turned profit |
| EPS, basic (₹) | 0.06 | 15.47 | −99.6% | (38.85) | Turned profit |
| Net margin (%) | 0.1 | 12.9 | -139.1 |
Consolidated
- Filed with BSE
- 30 Apr 2022, 13:21 IST
- Board meeting
- 29 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Apr 2022, 13:21 IST
- Board meeting
- 29 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE